Empiric Antibiotic Therapy for Staphylococcus aureus Pneumonia

Introduction to Antibiotic Selection

The Infectious Diseases Society of America recommends empiric coverage for Staphylococcus aureus pneumonia to include an anti-staphylococcal agent plus antipseudomonal coverage, with MRSA-active therapy indicated when risk factors are present or local MRSA prevalence exceeds 10-20% 1, 2

Cover for MRSA if prior intravenous antibiotic use within 90 days, treatment in units where >10-20% of S. aureus isolates are methicillin-resistant, unknown local MRSA prevalence, septic shock at time of pneumonia, ARDS preceding pneumonia, five or more days of hospitalization prior to pneumonia onset, or acute renal replacement therapy prior to onset 1, 2, 3
Cover for MSSA only if no risk factors for antimicrobial resistance present, treatment in ICUs where <10-20% of S. aureus isolates are methicillin-resistant, and no prior antibiotic exposure 1, 3, 4

For MRSA coverage, first-line options include vancomycin 15 mg/kg IV q8-12h or linezolid 600 mg IV q12h, with a loading dose of 25-30 mg/kg × 1 for severe illness considered for vancomycin 1, 2
For MSSA coverage, choose one of the following: piperacillin-tazobactam 4.5 g IV q6h, cefepime, levofloxacin 750 mg IV daily, or imipenem or meropenem 1, 2, 3

All empiric regimens must include coverage for Pseudomonas aeruginosa and other gram-negative bacilli, which is a strong recommendation regardless of whether MRSA or MSSA coverage is chosen 1, 5, 6
A single antipseudomonal agent is sufficient unless prior IV antibiotic use within 90 days, high risk for mortality, structural lung disease, or mechanical ventilation >7-8 days 2, 4

Before initiating antibiotics, obtain sputum Gram stain and culture, and consider bronchoscopy with quantitative cultures in ventilated patients 4, 5, 6
Within 48-72 hours, reassess clinical response, review culture and susceptibility results, and de-escalate therapy based on microbiology to narrow spectrum agents 1, 2, 4, 5

Do not use vancomycin monotherapy for severe MRSA pneumonia without considering linezolid or combination therapy with clindamycin/rifampicin, especially if PVL-positive 4
Do not omit antipseudomonal coverage even when S. aureus is isolated, as polymicrobial infection is common 1, 5
Do not prolong antibiotics unnecessarily to prevent recurrences, as this does not reduce relapse rates and promotes resistance 4
Do not treat Candida colonization in sputum unless there is histologic evidence or isolation from sterile sites 4